Monopar Therapeutics announces pricing of a $40 million stock offering to fund research and development initiatives.
Quiver AI Summary
Monopar Therapeutics Inc., a biotechnology company, has announced the pricing of an underwritten registered offering of 798,655 shares of its common stock at $23.79 per share, along with a private placement of pre-funded warrants for 882,761 shares at $23.789 each. The total expected gross proceeds from these offerings are around $40 million, which will be used for general corporate purposes, including research and development, clinical trials, and working capital. The offerings are set to close by December 23, 2024, pending customary conditions. Monopar's clinical-stage projects include treatments for Wilson disease and advanced cancers. The offerings are conducted under a registration statement declared effective by the SEC, and further details will be made available through the SEC's website.
Potential Positives
- Monopar Therapeutics successfully priced an underwritten registered offering of 798,655 shares of common stock, raising significant capital for the company.
- The total expected gross proceeds from both the registered offering and the concurrent private placement amount to $40 million, which will support the company's development initiatives.
- The participation of notable investors such as RA Capital Management and Janus Henderson Investors highlights confidence in Monopar's business and growth potential.
- The funds raised are intended for general corporate purposes, which may include research and development, positioning Monopar for future advancements in their clinical programs.
Potential Negatives
- The company is engaging in an underwritten public offering, which can be perceived as a sign of financial instability or a need for immediate capital, potentially leading to shareholder dilution.
- The announcement that the proceeds will be used for general corporate purposes, including research and development, may raise concerns about the effectiveness of their current strategies or existing cash flow issues.
- The reliance on multiple large investors for this offering could indicate a lack of broader market confidence in the company's financial health or product pipeline.
FAQ
What is the latest offering by Monopar Therapeutics?
Monopar Therapeutics announced an underwritten registered offering of 798,655 common stock shares at $23.79 per share.
How much capital is Monopar expected to raise?
The company is expected to raise approximately $40 million from the offering and private placement.
When is the offering expected to close?
The offering is expected to close on or about December 23, 2024, subject to customary closing conditions.
What are the intended uses for the proceeds?
Monopar intends to use the net proceeds for general corporate purposes, including research, development, and clinical trial expenditures.
Who managed the offering for Monopar?
Piper Sandler & Co. acted as the sole book-running manager for the registered offering.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MNPR Insider Trading Activity
$MNPR insiders have traded $MNPR stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $MNPR stock by insiders over the last 6 months:
- KARTHIK RADHAKRISHNAN (Chief Financial Officer) purchased 1,550 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Full Release
WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) --
Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”)
, a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 798,655 shares of its common stock at an offering price of $23.79 per share. In addition to the shares sold in the registered offering, Monopar announced the concurrent pricing of a private placement of pre-funded warrants to purchase 882,761 shares of common stock at a purchase price of $23.789 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The gross proceeds to Monopar from the registered offering and private placement, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be $40 million. The offering is expected to close on or about December 23, 2024, subject to customary closing conditions.
Monopar intends to use the net proceeds from the offering for general corporate purposes, which may include research and development expenditures, clinical trial expenditures, manufacture and supply of product, and working capital.
RA Capital Management, Janus Henderson Investors, Adage Capital Partners LP and ADAR1 Capital Management participated in the offering.
Piper Sandler & Co. is acting as the sole book-running manager for the offering.
The securities in the registered offering are being offered and sold pursuant to a "shelf" registration statement on Form S-3 (File No. 333-268935), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 21, 2022, and declared effective on January 4, 2023. A prospectus supplement and accompanying prospectus describing the terms of the registered offering will be filed with the SEC and will be available on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the registered offering, when available, may also be obtained by contacting Piper Sandler & Co. by mail at Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924 or by email at
prospectus@psc.com
.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biotechnology company with late-stage ALXN-1840 for Wilson disease, and radiopharma programs including Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers. For more information, visit: www.monopartx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of these forward-looking statements include statements concerning: statements regarding the completion of the offering, the satisfaction of customary closing conditions related to the offering and the anticipated use of proceeds therefrom. The forward-looking statements involve risks and uncertainties including, but not limited to: our ability to raise sufficient funds in order for us to support continued clinical, regulatory and commercial development of our programs and to make contractual future milestone payments, as well as our ability to further raise additional funds in the future to support any existing or future product candidate programs through completion of clinical trials, the approval processes and, if applicable, commercialization; uncertainties related to the regulatory discussions we intend to initiate related to ALXN-1840 and the outcome thereof; the rate of market acceptance and competitiveness in terms of pricing, efficacy and safety, of any products for which we receive marketing approval, and our ability to competitively market any such products as compared to larger pharmaceutical firms; and the significant general risks and uncertainties surrounding the research, development, regulatory approval, and commercialization of imaging agents and therapeutics. Actual results may differ materially from those expressed or implied by such forward-looking statements. Risks are described more fully in Monopar's filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Monopar undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Any forward-looking statements contained in this press release represent Monopar’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
CONTACT:
Monopar Therapeutics Inc.
Investor Relations
Karthik Radhakrishnan
Chief Financial Officer
karthik@monopartx.com
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
